

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI807030

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
SEQUENCE:	3	
CONVEYING PARTY DATA		
	Name	Execution Date
	WuXi STA Pharmaceutical Co. Ltd.	12/02/2022
RECEIVING PARTY DATA		
Company Name:	Flare Therapeutics Inc.	
Street Address:	215 First Street, Suite 150	
City:	Cambridge	
State/Country:	MASSACHUSETTS	
Postal Code:	02142	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	18130121
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6174496500	
Email:	mlombardo@mccarter.com	
Correspondent Name:	Michael DeGrazia	
Address Line 1:	McCarter & English LLP	
Address Line 2:	265 Franklin Street	
Address Line 4:	Boston, MASSACHUSETTS 02110	
ATTORNEY DOCKET NUMBER:	132266-00303	
NAME OF SUBMITTER:	Michelle Lombardo	
SIGNATURE:	/Michelle Lombardo/	
DATE SIGNED:	02/07/2025	
Total Attachments: 4		
source=WuXi STA Pharma to Flare Therapeutics Fully Executed Assignment 07-29-24#page1.tiff		
source=WuXi STA Pharma to Flare Therapeutics Fully Executed Assignment 07-29-24#page2.tiff		
source=WuXi STA Pharma to Flare Therapeutics Fully Executed Assignment 07-29-24#page3.tiff		
source=WuXi STA Pharma to Flare Therapeutics Fully Executed Assignment 07-29-24#page4.tiff		

ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, WuXi STA Pharmaceutical Co. Ltd., having its principal place of business at 90 Delin Road, WaiGaoQiao Free Trade Zone, Shanghai 200131, China (hereinafter referred to as "ASSIGNOR") has sold, assigned, and transferred, and by these presents hereby sells, assigns, and transfers, unto

Flare Therapeutics Inc.
215 First Street, Suite 150
Cambridge, Massachusetts 02142
United States of America

(hereinafter referred to as "ASSIGNEE") its successors and assigns, the full and exclusive right, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to

PPARG INVERSE AGONISTS AND USES THEREOF


as set forth in the following Patent Applications:

International Application No. PCT/CN2022/129034, filed November 1, 2022
Argentine Patent Application No. 20220102982, filed November 1, 2022
Taiwanese Patent Application No. 111141614, filed November 1, 2022

which claim the benefit of the following Applications:

United States Provisional Application No. 63/347,671, filed June 1, 2022
United States Provisional Application No. 63/274,596, filed November 2, 2021

Including (a) all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions, (b) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (c) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (d) the right to claim for any of said applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.



ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **McCarter & English, LLP** the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of **McCarter & English, LLP** do not personally represent ASSIGNOR OR ASSIGNOR's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

ASSIGNOR:

WuXi STA Pharmaceutical Co. Ltd.

Executed this 2nd day of December, 2022.



Name: Xianghui Wen
Title: VP, Process R&D

Witness Signature:




Date: Dec. 2nd, 2022

Printed Name:

Bo Zheng

Witness Signature:



Date: Dec. 2nd, 2022

Printed Name:

Fei Wang

Acceptance of Assignment by the Assignee:

Flare Therapeutics Inc.

Executed this 29th day of July, 2024.



Name: ROBERT HOLMAN
Title: ASSIST. TREASURER

Witness Signature: _____

Date: _____


Printed Name: _____

Witness Signature: _____

Date: _____

Printed Name: _____

On this 29 day of July, 2024, before me, the undersigned notary public, personally appeared Robert Holman (name of document signer), proved to me through satisfactory evidence of identification, which were Drivers Lic., to be the person whose name is signed on the preceding or attached document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of (his) (her) knowledge and belief.



(official signature and seal of notary)

